Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease

Table 3 Comparison of non-invasive biomarkers of hepatic fibrosis between patients found to have hepatic steatosis and those without steatosis on imaging

Biomarker	Data by hepatic steatosis		P value
	Hepatic steatosis (n = 17, 15%)	No hepatic steatosis (n = 97, 85%)
APRI	0.28 (0.14-0.27)	0.19 (0.12-0.32)	0.579
FIB-4	0.49 (0.35-0.67)	0.57 (0.36-0.82)	0.629
AAR	0.79 (0.65-1.08)	1.00 (0.82-1.33)	0.017a

^aP < 0.05. APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis 4 score; AAR: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio.